- Home
- PXLW vs IFRX Comparison
PXLW vs IFRX Comparison
Compare PXLW & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PXLW
- IFRX
- Stock Information
- Founded
- PXLW 1997
- IFRX 2007
- Country
- PXLW United States
- IFRX Germany
- Employees
- PXLW N/A
- IFRX N/A
- Industry
- PXLW Semiconductors
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- PXLW Technology
- IFRX Health Care
- Exchange
- PXLW Nasdaq
- IFRX Nasdaq
- Market Cap
- PXLW 50.2M
- IFRX 53.5M
- IPO Year
- PXLW 2000
- IFRX 2017
- Fundamental
- Price
- PXLW $9.72
- IFRX $1.58
- Analyst Decision
- PXLW Strong Buy
- IFRX Strong Buy
- Analyst Count
- PXLW 3
- IFRX 5
- Target Price
- PXLW $13.67
- IFRX $7.40
- AVG Volume (30 Days)
- PXLW 120.1K
- IFRX 828.1K
- Earning Date
- PXLW 08-12-2025
- IFRX 11-07-2025
- Dividend Yield
- PXLW N/A
- IFRX N/A
- EPS Growth
- PXLW N/A
- IFRX N/A
- EPS
- PXLW N/A
- IFRX N/A
- Revenue
- PXLW $33,961,000.00
- IFRX $191,224.00
- Revenue This Year
- PXLW N/A
- IFRX N/A
- Revenue Next Year
- PXLW $25.33
- IFRX $1,336.36
- P/E Ratio
- PXLW N/A
- IFRX N/A
- Revenue Growth
- PXLW N/A
- IFRX 54.36
- 52 Week Low
- PXLW $4.67
- IFRX $0.71
- 52 Week High
- PXLW $15.03
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- PXLW 55.03
- IFRX 71.63
- Support Level
- PXLW $7.97
- IFRX $1.45
- Resistance Level
- PXLW $8.62
- IFRX $1.82
- Average True Range (ATR)
- PXLW 0.97
- IFRX 0.15
- MACD
- PXLW 0.06
- IFRX 0.07
- Stochastic Oscillator
- PXLW 62.25
- IFRX 76.00
About PXLW Pixelworks Inc.
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.